From the Nipah Virus International Conference in Singapore, Vincent speaks with Richard Hatchett, CEO of CEPI, about its mission to stimulate and accelerate the development of vaccines against emerging infectious diseases.
Daniel Griffin provides a weekly clinical update on COVID-19, then Michael Schmidt discusses how dentistry can be safely practiced during a pandemic, followed by answers to listener questions.
The TWiV team summarizes serology-based tests for SARS-CoV-2, lack of effect of ACE inhibitors or ARBs on COVID-19 severity, and answers listener questions.
Susan Weiss recalls some of her 40 years of research on coronaviruses, including mouse hepatitis virus, MERS-CoV, and now SARS-CoV-2.
Daniel Griffin updates the clinical situation with COVID-19 patients, followed by analysis of the remedesivir clinical trial results, and answers listener questions.
Jeff Shaman returns to TWiV to explain why more SARS-CoV-2 testing and contact tracing is needed to stop the pandemic, insights on immunity and reinfection from seasonal CoVs, the problems with antibody tests, and what to expect in the coming months.
Daniel Griffin provides his weekly update on the COVID-19 clinical situation, followed by our discussion of tests of an inactivated vaccine, results of serological surveys, an inhibitor of the cell protease needed for virus entry, and answers to listener questions.
Ralph Baric, Mark Heise and Nat Moorman discuss their non-profit initiative READDI, Rapidly Emerging Antiviral Drug Discovery Initiative, to start making drugs now for the next pandemic virus.
Kostya Chumakov discusses the hypothesis that oral poliovirus vaccine can provide non-specific protection against many other viruses, and might prevent infection with SARS-CoV-2.
Daniel Griffin provides his weekly update on the COVID-19 clinical situation, followed by results of seroprevalence studies, analysis of CpG dinucleotide frequencies in the SARS-CoV-2 genome, and answers to listener questions.